[go: up one dir, main page]

LT3251503T - Pelės genų inžinerija, siekiant produkuoti chimerinius antikūnus - Google Patents

Pelės genų inžinerija, siekiant produkuoti chimerinius antikūnus

Info

Publication number
LT3251503T
LT3251503T LTEP17178066.1T LT17178066T LT3251503T LT 3251503 T LT3251503 T LT 3251503T LT 17178066 T LT17178066 T LT 17178066T LT 3251503 T LT3251503 T LT 3251503T
Authority
LT
Lithuania
Prior art keywords
mice
production
genetic engineering
chimeric antibodies
chimeric
Prior art date
Application number
LTEP17178066.1T
Other languages
English (en)
Inventor
Larry Green
Hiroaki Shizuya
Original Assignee
Ablexis, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44712850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3251503(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ablexis, Llc filed Critical Ablexis, Llc
Publication of LT3251503T publication Critical patent/LT3251503T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LTEP17178066.1T 2010-03-31 2011-03-31 Pelės genų inžinerija, siekiant produkuoti chimerinius antikūnus LT3251503T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31969010P 2010-03-31 2010-03-31
US36130210P 2010-07-02 2010-07-02

Publications (1)

Publication Number Publication Date
LT3251503T true LT3251503T (lt) 2024-05-10

Family

ID=44712850

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP17178066.1T LT3251503T (lt) 2010-03-31 2011-03-31 Pelės genų inžinerija, siekiant produkuoti chimerinius antikūnus
LTEP17178088.5T LT3248462T (lt) 2010-03-31 2011-03-31 Pelių genų inžinerija, skirta chimerinių antikūnų gamybai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP17178088.5T LT3248462T (lt) 2010-03-31 2011-03-31 Pelių genų inžinerija, skirta chimerinių antikūnų gamybai

Country Status (11)

Country Link
US (16) US9580491B2 (lt)
EP (5) EP3251503B1 (lt)
KR (7) KR20210010942A (lt)
AU (1) AU2011234988B2 (lt)
CA (3) CA3006810C (lt)
DK (3) DK3248462T3 (lt)
ES (3) ES2641920T3 (lt)
LT (2) LT3251503T (lt)
NZ (1) NZ601171A (lt)
PL (3) PL3248462T3 (lt)
WO (1) WO2011123708A2 (lt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
KR20210010942A (ko) 2010-03-31 2021-01-28 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
EP2597945B1 (en) 2010-07-26 2020-07-22 Trianni, Inc. Transgenic animals and methods of use
CN103842379A (zh) 2011-03-09 2014-06-04 细胞信号科技公司 用于生成单克隆抗体的方法和试剂
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
CN106414717B (zh) * 2014-05-02 2021-05-04 凯奥目生物科学株式会社 产生人抗体的细胞
RU2018110364A (ru) * 2015-08-24 2019-09-26 Трианни, Инк. Усовершенствованное продуцирование иммуноглобулинов
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
WO2017136734A1 (en) 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
GB2561352B (en) 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
SG11202002002XA (en) 2017-09-29 2020-04-29 Regeneron Pharma Non-human animals expressing humanized c1q complex
WO2019152895A1 (en) 2018-02-01 2019-08-08 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
WO2019182751A1 (en) * 2018-03-21 2019-09-26 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
US20210051929A1 (en) 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CN108486125B (zh) * 2018-03-27 2024-01-05 重庆金迈博生物科技有限公司 一种核酸分子及其在制备人源单域抗体中的应用
WO2019224579A1 (en) 2018-05-23 2019-11-28 Arcelormittal A method for the manufacture of reduced graphene oxide from electrode graphite scrap
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CA3147735A1 (en) 2019-07-26 2021-02-04 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
CA3148735A1 (en) 2019-07-26 2021-02-04 Janssen Biotech, Inc. Anti-hk2 chimeric antigen receptor (car)
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
JP2023528350A (ja) 2020-05-27 2023-07-04 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ３抗原結合ドメインを含むタンパク質及びその使用
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
WO2022132923A1 (en) 2020-12-16 2022-06-23 Voyager Therapeutics, Inc. Tau binding compounds
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
IL303868A (en) 2020-12-23 2023-08-01 Regeneron Pharma Nucleic acids encoding anchor-modified antibodies and uses thereof
CA3205707A1 (en) 2021-01-27 2022-08-04 Fei Shen Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
MX2023011267A (es) 2021-03-24 2023-12-14 Janssen Biotech Inc Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3.
CN118511853A (zh) 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
PE20240727A1 (es) 2021-08-27 2024-04-15 Janssen Biotech Inc Anticuerpos anti-psma y usos de estos
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
US20240392313A1 (en) * 2021-11-16 2024-11-28 National University Corporation Tottori University Mammalian artificial chromosome vector having human immunoglobulin heavy chain locus comprising modified d-region, and cell or non-human animal retaining the vector
AU2023214183A1 (en) 2022-01-26 2024-09-12 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
EP4543473A1 (en) 2022-06-22 2025-04-30 Voyager Therapeutics, Inc. Tau binding compounds
AU2023367039A1 (en) 2022-10-25 2025-05-15 Ablexis, Llc Anti-cd3 antibodies
WO2024107731A2 (en) 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies
WO2025158009A1 (en) 2024-01-26 2025-07-31 Almirall S.A. Bispecific molecules and methods of treatment using the same

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1270107A (en) 1917-12-07 1918-06-18 John Latson Boardman Stretcher.
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1990000616A1 (en) 1988-07-07 1990-01-25 Michael Neumaier Recombinomas
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6689610B1 (en) 1989-08-22 2004-02-10 University Of Utah Research Foundation Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU654284B2 (en) 1990-06-12 1994-11-03 Baylor College Of Medicine Method for homologous recombination in animal and plant cells
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
GB9119338D0 (en) 1991-09-10 1991-10-23 Inst Of Animal Physiology And Control of gene expression
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE4228162C1 (de) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
ES2176574T3 (es) 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
BR9808584A (pt) 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6090554A (en) 1997-10-31 2000-07-18 Amgen, Inc. Efficient construction of gene targeting vectors
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
WO2001032712A2 (en) * 1999-11-03 2001-05-10 Maxygen, Inc. Antibody diversity generation
EP1274854B1 (en) 2000-04-12 2009-04-08 Dana-Farber Cancer Institute Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1440146A4 (en) 2001-06-26 2005-06-22 Genome Biosciences Llc PROCESS AND VECTORS FOR THE TARGETING OF GENES
US6881557B2 (en) * 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
WO2003027261A2 (en) 2001-09-27 2003-04-03 Functional Genetics, Inc. Methods and compositions for gene targeting by homologous recombination
EP1461442B1 (en) * 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
AU2002351233A1 (en) 2001-12-04 2003-06-17 Genome Biosciences, Llc Gene targeting methods and vectors
JP3743394B2 (ja) 2002-05-31 2006-02-08 株式会社村田製作所 赤外線センサおよびそれを用いた電子装置
TW588243B (en) 2002-07-31 2004-05-21 Trek 2000 Int Ltd System and method for authentication
EP1539946A4 (en) 2002-09-09 2006-03-15 California Inst Of Techn METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
JP2006520610A (ja) * 2003-03-04 2006-09-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド ハイブリッド不変領域を産生するのに用いるベクター
US7205148B2 (en) 2003-06-11 2007-04-17 Regeneron Pharmaceuticals, Inc. Genome mutation by intron insertion into an embryonic stem cell genome
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
WO2005019463A1 (en) 2003-08-11 2005-03-03 Therapeutic Human Polyclonals, Inc. Improved transgenesis with humanized immunoglobulin loci
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
US20050191293A1 (en) 2003-12-10 2005-09-01 Shrikant Deshpande IP-10 antibodies and their uses
US20060117398A1 (en) 2004-10-22 2006-06-01 Roland Buelow Suppression of endogenous immunoglobulin expression
WO2006072803A2 (en) 2005-01-10 2006-07-13 Medical Research Council Antibody
WO2006117699A2 (en) * 2005-04-29 2006-11-09 Innate Pharma Transgenic animals and methods of making recombinant antibodies
EP2520588A1 (en) * 2005-08-19 2012-11-07 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CA2661848C (en) 2006-09-01 2015-02-03 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
WO2008090958A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
SG182144A1 (en) 2007-06-01 2012-07-30 Omt Inc Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
EP2669298A3 (en) 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
ES2445193T3 (es) 2008-06-27 2014-02-28 Merus B.V. Mamíferos no humanos productores de anticuerpos
WO2010003990A1 (en) 2008-07-10 2010-01-14 Frewitt Fabrique De Machines S.A. Bead mill with separator
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
KR101711222B1 (ko) 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
ES2948572T3 (es) 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
MY172472A (en) 2009-12-10 2019-11-26 Regeneron Pharma Mice that make heavy chain antibodies
KR20210010942A (ko) 2010-03-31 2021-01-28 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
CA2802591A1 (en) * 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
MY195217A (en) 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
EP2597945B1 (en) * 2010-07-26 2020-07-22 Trianni, Inc. Transgenic animals and methods of use

Also Published As

Publication number Publication date
EP3251503B1 (en) 2024-03-20
US20170190797A1 (en) 2017-07-06
KR20210010942A (ko) 2021-01-28
US11104744B2 (en) 2021-08-31
US9580491B2 (en) 2017-02-28
US20200407465A1 (en) 2020-12-31
KR20130018259A (ko) 2013-02-20
US10618977B2 (en) 2020-04-14
ES2641920T3 (es) 2017-11-14
ES2984483T3 (es) 2024-10-29
AU2011234988A1 (en) 2012-10-18
CA3006800A1 (en) 2011-10-06
KR102117771B1 (ko) 2020-06-02
EP3251503A1 (en) 2017-12-06
US20170188557A1 (en) 2017-07-06
KR101831117B1 (ko) 2018-04-04
US20200181286A1 (en) 2020-06-11
US20200407466A1 (en) 2020-12-31
EP3248462B1 (en) 2024-03-13
AU2011234988B2 (en) 2014-10-30
PL3248462T3 (pl) 2024-07-08
PL2553100T3 (pl) 2018-03-30
US20170218090A1 (en) 2017-08-03
US10836832B2 (en) 2020-11-17
KR20180030941A (ko) 2018-03-26
EP4345164A2 (en) 2024-04-03
CA3006810C (en) 2022-01-11
US20210002385A1 (en) 2021-01-07
EP4345164A3 (en) 2024-06-26
ES2984484T3 (es) 2024-10-29
CA2787498A1 (en) 2011-10-06
US20170190794A1 (en) 2017-07-06
US20200407464A1 (en) 2020-12-31
US11220555B2 (en) 2022-01-11
KR102203727B1 (ko) 2021-01-18
PL3251503T3 (pl) 2024-07-08
KR102004106B1 (ko) 2019-07-25
KR20180018835A (ko) 2018-02-21
US20200377619A1 (en) 2020-12-03
CA2787498C (en) 2018-06-26
US10626188B2 (en) 2020-04-21
KR101667440B1 (ko) 2016-10-18
US11242409B2 (en) 2022-02-08
DK3248462T3 (da) 2024-05-06
US20170188558A1 (en) 2017-07-06
EP4345163A3 (en) 2024-06-19
US20170181414A1 (en) 2017-06-29
US10526420B2 (en) 2020-01-07
US20130167256A1 (en) 2013-06-27
WO2011123708A3 (en) 2012-01-19
CA3006800C (en) 2022-10-04
DK3251503T3 (da) 2024-05-06
KR20170042382A (ko) 2017-04-18
NZ601171A (en) 2014-11-28
EP4345163A2 (en) 2024-04-03
US20170190796A1 (en) 2017-07-06
US20200181285A1 (en) 2020-06-11
US10662255B2 (en) 2020-05-26
KR101830020B1 (ko) 2018-02-19
EP2553100A2 (en) 2013-02-06
US10829564B2 (en) 2020-11-10
KR20180030942A (ko) 2018-03-26
EP2553100B1 (en) 2017-07-05
US11352444B2 (en) 2022-06-07
KR20160120794A (ko) 2016-10-18
CA3006810A1 (en) 2011-10-06
EP2553100A4 (en) 2013-10-23
EP3248462A1 (en) 2017-11-29
DK2553100T3 (en) 2017-10-23
LT3248462T (lt) 2024-05-27
WO2011123708A2 (en) 2011-10-06
US10604587B2 (en) 2020-03-31
US11104743B2 (en) 2021-08-31
US20170190795A1 (en) 2017-07-06
US10494445B2 (en) 2019-12-03

Similar Documents

Publication Publication Date Title
PL3248462T3 (pl) Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
LT2346994T (lt) Knock-in pelė, skirta chimerinių antikūnų gamybai
IL217381A0 (en) Optimizing the production of antibodies
ZA201300146B (en) Process for the production of para-xylene
EP2552874A4 (en) PROCESS FOR PREPARING HEXAFLUOR-2 BUTENE
IL230522B (en) Methods for the synthesis of functional nucleic acids
PL2780307T3 (pl) Sposób wytwarzania fluorowodoroolefin
ZA201304696B (en) Anti-cd38 antibodies
SG10201506492PA (en) Improved antibodies of the class igg4
SG10201508779UA (en) Process for the production of paraxylene
EP2558432A4 (en) METHOD FOR THE PRODUCTION OF TETRAFLUOROLEFINES
PL2531286T3 (pl) Sposób syntezy metanolu
GB201001791D0 (en) Process for obtaining antibodies
LT2696959T (lt) Aplinkai nekenksmingas cemento gamybos būdas
ZA201300776B (en) Improved process for the preparation of febuxostat
IL226677A (en) Beta-amyloid production compounds
ZA201408554B (en) Process for the production of methyl methacrylate
ZA201205844B (en) Process for the production of anhydrides
HUE044066T2 (hu) Eljárás metilén-difenil-diizocianát elõállítására
ZA201404385B (en) Process for the manufacture of ferrochrome
SMT201800111T1 (it) Processo per la produzione di cefalosporine
PL396363A1 (pl) Fotobioreaktor do produkcji biomasy, zwlaszcza z glonów
EG27168A (en) The technique of producing seedlings for black sapote
GB201000454D0 (en) Process for the production of hydrocarbons
PL392866A1 (pl) Beton do wykonywania elementów betonowych